Core Viewpoint - The company BaiO Saite-B (02315) has reported significant growth in its 2025 performance forecast, with a notable increase in revenue and net profit, driven by overseas market expansion and recovery in the domestic biopharmaceutical industry [1] Financial Performance - The expected revenue for 2025 is approximately 1.379 billion RMB, representing a year-on-year growth of 40.63% [1] - The net profit attributable to the company's owners is projected to be 173 million RMB, showing a substantial year-on-year increase of 416.37% [1] - The net profit attributable to the company's owners, excluding non-recurring gains and losses, is expected to be 116 million RMB, reflecting a year-on-year growth of 405.39% [1] Asset and Equity Growth - Total assets are anticipated to reach 3.724 billion RMB, an increase of 54.20% compared to the beginning of the period [1] - Equity attributable to the company's owners is projected to be 2.175 billion RMB, marking a significant increase of 160.76% from the beginning of the period [1] Strategic Drivers - The growth in operating performance is primarily attributed to the continuous expansion in overseas markets and the recovery of the domestic biopharmaceutical sector [1] - The company emphasizes an innovation-driven strategy, with sustained high-intensity R&D investment to build core technological barriers, ensuring stable high gross margins [1] - Lean management practices are being implemented to continuously enhance operational efficiency, contributing to rapid improvements in profitability [1]
百奥赛图-B再涨超5% 预计去年归母净利同比增长416.37% 海外市场持续拓展